MAPK
ターゲットにより製品を見付けてください
亜型選択性的な製品
SelleckはPD1/PDL1治療用抗体の販売を開始しました！（Pembrolizumab，Atezolizumab，Nivolumab）
- ホームページ
- 阻害剤
研究分野別
- PI3K/Akt/mTOR
- Epigenetics
- Methylation
- Immunology & Inflammation
- Protein Tyrosine Kinase
- Angiogenesis
- Apoptosis
- Autophagy
- ER stress & UPR
- JAK/STAT
- MAPK
- Cytoskeletal Signaling
- Cell Cycle
- HTS化合物ライブラリー
- FDA-approved Drug Library
- Clinical Compound Library
- Bioactive Compound Library-I
- Bioactive Compound Library-Ⅱ（Provided by Pfizer）
- Kinase Inhibitor Library
- Express-Pick Library (Provided by Pfizer)
- Natural Product Library
- Metabolism Compound Library
- Target Selective Inhibitor Library
- Epigenetics Compound Library
- Stem Cell Signaling Compound Library
- Inhibitor Library
- Apoptosis Compound Library
- FDA-approved Drug Library(Simplified Edition)
- GPCR Compound Library
- Cambridge Cancer Compound Library
- Immunology/Inflammation Compound Library
- Drug Repurposing Library
- Pfizer Licensed Compound Library
- MAPK Inhibitor Library
- Fragment Library
- Neuronal Signaling Compound Library
- PI3K/Akt Inhibitor Library
- Anti-diabetic Compound Library
- Anti-infection Compound Library
- Anti-cancer Compound Library
- Tyrosine Kinase Inhibitor Library
- Ion Channel Ligand Library
- Protease Inhibitor Library
- Autophagy Compound Library
- Bioactive Compound Library(Simplified Edition)
- Express-Pick Library (Premium Version)
- 治療用抗体
- 新製品
- お問い合わせ
